Piper Sandler assumed coverage on shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report published on Thursday, Marketbeat.com reports. The brokerage issued an overweight rating and a $9.00 target price on the stock. Other equities research analysts also recently issued research reports about the company. Noble Financial initiated coverage on Unicycive Therapeutics in […]